New asthma drug tested in diverse, Real-World patients

NCT ID NCT05329194

Completed Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

Summary

This study looked at how well and how safely the injectable medication tezepelumab works for people with severe asthma in real-world settings. It included 287 adults and adolescents whose asthma was not well controlled despite using standard high-dose inhalers and other controller medications. Participants received tezepelumab injections for 48 weeks, and researchers tracked whether it reduced serious asthma attacks, improved breathing, and lessened the need for emergency care or steroid pills.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Research Site

Hendersonville, Tennessee, 37075, United States
Research Site

Fort Worth, Texas, 76104, United States
Research Site

McKinney, Texas, 75069, United States
Research Site

San Antonio, Texas, 78229, United States
Research Site

Charlottesville, Virginia, 22903, United States
Research Site

Vancouver, Washington, 98664, United States
Research Site

Mobile, Alabama, 36608, United States
Research Site

Gilbert, Arizona, 85234, United States
Research Site

Long Beach, California, 90815, United States
Research Site

Los Angeles, California, 90017, United States
Research Site

Rancho Mirage, California, 92270, United States
Research Site

Westminster, California, 92683, United States
Research Site

Colorado Springs, Colorado, 80907, United States
Research Site

New Haven, Connecticut, 06510, United States
Research Site

Washington D.C., District of Columbia, 20037, United States
Research Site

Chicago, Illinois, 60611, United States
Research Site

Lexington, Kentucky, 40509, United States
Research Site

New Orleans, Louisiana, 70112, United States
Research Site

Upper Marlboro, Maryland, 20772, United States
Research Site

Ann Arbor, Michigan, 48109, United States
Research Site

Ypsilanti, Michigan, 48197, United States
Research Site

Saint Paul, Minnesota, 55109, United States
Research Site

St Louis, Missouri, 63110, United States
Research Site

Lincoln, Nebraska, 68505, United States
Research Site

Omaha, Nebraska, 68114, United States
Research Site

Hollis, New York, 11423, United States
Research Site

Horseheads, New York, 14845, United States
Research Site

Rochester, New York, 14642, United States
Research Site

Valhalla, New York, 10595, United States
Research Site

Chapel Hill, North Carolina, 27514, United States
Research Site

Wilmington, North Carolina, 28401, United States
Research Site

Toledo, Ohio, 43617, United States
Research Site

Oklahoma City, Oklahoma, 73120, United States
Research Site

Altoona, Pennsylvania, 16602, United States
Research Site

Philadelphia, Pennsylvania, 19140, United States
Research Site

Warwick, Rhode Island, 02886, United States
Research Site

Greenville, South Carolina, 29607, United States

Conditions

Explore the condition pages connected to this study.

ASTHMA